Glad to hear the kiddo is doing well, Mr. S.
Thank you for the additional information. You identify a problem with meta-analysis in general, one that extends beyond the policies of the FDA - a bias against publication of studies with negative results. I am frankly somewhat perturbed by the wide spread acceptance of meta-analysis as a research tool. It is better than a review, which doesn’t account for sample sizes, etc., but it is biased to finding positive results.
I will accept that the efficacy of antidepressants as a class remains unresolved. I’d be curious to see if the data on the newer SSRI’s are better. If I have the time I’ll try to do a little searching and see what I come up with. I’d also be interested if you have any reviews on studies related to the efficacy of the SSRI’s for anxiety and OCD. Here I have seen such dramatic effects first hand that I’d be very surprised if it was primarily placebo effect. But I’m not a psychiatrist, just a pediatrician with an interest in neurobiology, so I do not know the psychiatry literature all that well.
Interesting stuff. Irrelevant to the op of course, but a very interesting aside. As said before and in the Pit thread:
That mental conditions are “physiological” is a truism. Physiology is merely how the biological system works, whether it is the effect of genetic predisposition, of toxin, of infection, or behavioral experiences.
That mental conditions have, to various degrees depending on the condition under discussion and the individual case, biological inate contributors (nature) and experiential contributors (nurture) is irrefutable. That there are mechanisms by which the biologic predisposition occurs is inescapable.
“Disorder” is defined by maladaptive function within the organism’s environment. If a phenotype is associated with predictable poor outcome in the environment that the organism exists in, then that phenotype is a disorder. Whether the physiology is understood or not. Whether there are effective trreatments or not. And even if the phenotype would be adaptive in a different time and place.
The most effective way to study disorders is to pool information and experience across a community of researchers and clinicians. To do that you need to know that you are all talking about the same thing. The DSM is the best tool available to do that. It is far from perfect but it is a work in progress, not a static entity.
Treatment for different disorders is contigent upon risk/benefit analysis in individual cases. Not on whether we know all there is to know about the physiology, or whether or not we believe that a condition is all nature or all nurture. What works and at what cost/risk? You have presented some compelling arguments that the class of antidepressants as a whole may have been oversold. I remain to be informed about data specific to the more recent medications. The data for medication efficacy in other mental disorders is, in at least some cases, more solid. I am most familiar with ADD (being a pediatrician) and here medication has tested out as far superior to behavioral interventions alone, for example. I am less familiar with the data for anxiety and OCD, for example, but anecdotally have seen dramatic effects in freinds, family members, and others. This is not the same as a double blind control trial however so I could be convinced by strong data to the contrary.
Undestanding of the physiology of brain function is still embryonic. As you have a particular interest in schizophrenia, I refer you to work by Steven Grossberg for a wonderful model and also to Andreason’s work on the model of “cognitive dysmetria”. I think that these systems approaches will be most useful in the long term.
Thank you again for the informative post.